(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 10.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Capricor Therapeutics's revenue in 2024 is $27,098,247.On average, 2 Wall Street analysts forecast CAPR's revenue for 2024 to be $928,894,924, with the lowest CAPR revenue forecast at $585,331,048, and the highest CAPR revenue forecast at $1,272,458,800. On average, 2 Wall Street analysts forecast CAPR's revenue for 2025 to be $914,579,763, with the lowest CAPR revenue forecast at $715,758,075, and the highest CAPR revenue forecast at $1,113,401,450.
In 2026, CAPR is forecast to generate $1,197,701,846 in revenue, with the lowest revenue forecast at $1,170,662,096 and the highest revenue forecast at $1,224,741,595.